Coptis chinensis Polysaccharides Inhibit Advanced Glycation End Product Formation.
Coptis chinensis Polysaccharides Inhibit Advanced Glycation End Product Formation.
复制标题
DOI：
10.1089/jmf.2015.3606
复制
发表时间：
2016-06
影响因子：
2.4
通讯作者：
Ye Yang;Yun Li;Dengke Yin;Song Chen;Xiangdong Gao
中科院分区：
文献类型：
--
作者：
Ye Yang;Yun Li;Dengke Yin;Song Chen;Xiangdong Gao
黄连是我国常用的治疗糖尿病的药物。在本研究中，C。研究了中药黄芪多糖（CCP）对糖基化终产物（AGE）形成的影响。CCP显著抑制Amadori产物、二羰基化合物和AGE的形成（P <0.01）。在糖尿病小鼠中，给予CCP不仅改善体重和血清胰岛素，降低空腹血糖和糖化血清蛋白浓度，而且还减少胰腺和肝脏中AGE的积聚和形态学异常。CCP对AGE形成的抑制作用为糖尿病的预防和治疗提供了潜在的治疗用途。
Coptis chinensis Franch (Huanglian) is commonly used to treat diabetes in China. In this study, the effects of the C. chinensis Franch polysaccharides (CCP) on advanced glycation end product (AGE) formation in vitro and in streptozotocin-induced diabetic mice were investigated. CCP significantly inhibited all the three periods of nonenzymatic protein glycation in vitro, including Amadori product, dicarbonyl compound, and AGE formation (P < .01). In diabetic mice, the administration of CCP not only improved both bodyweight and serum insulin and decreased fasting blood glucose and glycated serum protein concentrations but also decreased the AGE accumulations and morphological abnormalities in pancreas and liver. The inhibitory effects of CCP on AGE formation afford a potential therapeutic use in the prevention and treatment of diabetes.